C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis

T P Zwaka1, V Hombach, J Torzewski

  • 1Internal Medicine II-Cardiology, University of Ulm, Ulm, Germany.

Circulation
|March 10, 2001
PubMed

Insights

C-reactive protein (CRP) may help low-density lipoprotein (LDL) deposit in arteries, leading to foam cell formation. Macrophages take up CRP-opsonized LDL via macropinocytosis, contributing to atherosclerosis.

Area of Science:

  • Cardiovascular Biology
  • Immunology
  • Cell Biology

Background:

  • Low-density lipoprotein (LDL) and C-reactive protein (CRP) are key cardiovascular risk factors.
  • Both LDL and CRP accumulate in arterial walls during atherosclerosis.
  • Native LDL does not induce foam cell formation, suggesting a role for other factors.

Purpose of the Study:

  • To investigate if C-reactive protein (CRP) opsonizes native LDL for uptake by macrophages.
  • To elucidate the mechanism of CRP-mediated LDL uptake by macrophages.

Main Methods:

  • Isolation of human monocytes and differentiation into macrophages.
  • Assessment of CRP/LDL uptake using immunofluorescent labeling and confocal laser scanning microscopy.
  • Investigating the role of the CRP receptor CD32 in CRP/LDL uptake.

Main Results:

  • Macrophages readily took up native LDL when coincubated with CRP.
  • This uptake occurred via a process called macropinocytosis.
  • The CRP receptor CD32 was identified as the mediator of CRP/LDL uptake.

Conclusions:

  • CRP opsonizes native LDL, facilitating its uptake by macrophages.
  • Macrophage uptake of CRP-opsonized LDL contributes to foam cell formation.
  • This mechanism offers a potential explanation for foam cell formation in human atherogenesis.
Abstract

Related Concept Videos

Receptor-mediated Endocytosis01:38

Receptor-mediated Endocytosis

Overview
105.4K
Inflammation01:38

Inflammation

Overview
46.6K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741